Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany

<div>(a) Median number of ranibizumab injections with the first and third quartiles for patients receiving ≤4 OCT examinations or ≥8 OCT examinations for the matched sample (<i>N</i> = 411 for both groups); (b) median number of OCT examinations with the first and third quartiles for patients receiving ≤4 OCT examinations or ≥8 OCT examinations for the matched sample (<i>N</i> = 411 for both groups). OCT: optical coherence tomography.</div>

Journal of Ophthalmology

fig3

Figure 3

Figure 3: Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany 

Figure 3 | Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany 